Details of proposed European PFAS ban released Today, the European Chemicals Agency (ECHA) published details of a proposed ban on the production, use, sale and import of some 10,000 per- and polyfluoroalkyl substances (PFAS).
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
Key persons should be involved in policy for pandemics RIVM advises government authorities to involve ‘key persons’ in formulating policy for current and future pandemics. Results from RIVM research show that these individuals played a key role in ensuring an ongoing focus on social well-being and mental health during the COVID-19 pandemic, despite the limitations.
Grey heron infected with West Nile virus A grey heron in the Noord-Holland-Noord region has tested positive for the West Nile virus. The virus is rare in the Netherlands. Bas van de Meulengraaf
PFAS levels in drinking water from river water need to be brought down The National Institute for Public Health and the Environment (RIVM) advises to reduce PFAS concentrations in the drinking water in parts of the Netherlands in the coming years. This concerns drinking water produced from river water.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.